Somatropin - Biologic Drug Details

Summary for somatropin

Tradenames:	11
High Confidence Patents:	17
Applicants:	9
BLAs:	10
Suppliers: see list	7
Recent Clinical Trials:	See clinical trials for somatropin
Drug Prices:	Drug price information for somatropin

Recent Clinical Trials for somatropin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Beni-Suef University	PHASE2
Sunnybrook Research Institute	PHASE1
Dr. David Wasserstein	PHASE1

See all somatropin clinical trials

Pharmacology for somatropin

Established Pharmacologic Class	Recombinant Human Growth Hormone
Chemical Structure	Human Growth Hormone

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for somatropin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for somatropin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	5,334,162	2013-03-15	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	5,383,865	2013-03-15	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	5,454,786	2014-03-28	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NORDITROPIN	somatropin	Injection	021148	5,618,697	2015-01-13	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NORDITROPIN	somatropin	Injection	021148	5,626,566	2014-03-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for somatropin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10,016,338	2036-12-20	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10,045,943	2036-04-08	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10,154,856	2034-02-06	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10,335,463	2037-11-28	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10,364,451	2036-12-21	Patent claims search

International Patents for somatropin

Country	Patent Number	Estimated Expiration
Taiwan	I606062
Australia	2013221877
Australia	2008216896
Croatia	P20120947
World Intellectual Property Organization (WIPO)	9312812

Supplementary Protection Certificates for somatropin

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
25/2022	Austria		PRODUCT NAME: LONAPEGSOMATROPIN; REGISTRATION NO/DATE: EU/1/21/1607 (MITTEILUNG) 20220117
SPC008/2003	Ireland		SPC008/2003: 20030508, EXPIRES: 20121217
2290023-7	Sweden		PRODUCT NAME: LONAPEGSOMATROPIN; REG. NO/DATE: EU/1/21/1607 20220117
CR 2022 00020	Denmark		PRODUCT NAME: LONAPEGSOMATROPIN; REG. NO/DATE: EU/1/21/1607 20220117
22C1029	France		PRODUCT NAME: LONAPEGSOMATROPINE; REGISTRATION NO/DATE: EU/1/21/1607 20220117

Somatropin Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Market Overview and Growth Drivers

The global somatropin market is projected to reach $6.8 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2023. [1] Growth is driven by the increasing prevalence of growth hormone deficiency (GHD) in children and adults, alongside the expanding therapeutic applications of somatropin, including Turner syndrome, idiopathic short stature, and Prader-Willi syndrome. [2] The pediatric GHD segment is the largest market contributor, accounting for approximately 70% of the total somatropin market. [3]

Technological advancements in drug delivery systems, such as long-acting formulations and auto-injectors, are improving patient compliance and market penetration. [4] The development of biosimil somatropin products has also intensified market competition, leading to price erosion and increased accessibility for patients. [5]

Key Market Segments and Geographic Distribution

The somatropin market is segmented by product type (recombinant human growth hormone, rhGH), application (pediatric GHD, adult GHD, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, cachexia, others), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies). [6]

North America holds the largest market share, driven by a high GHD prevalence and robust healthcare infrastructure. [7] The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare expenditure, rising awareness of GHD, and a growing patient population. [8]

Competitive Landscape and Key Players

The somatropin market is characterized by the presence of both originator and biosimilar manufacturers. Key players include:

• Novo Nordisk A/S: Offers Norditropin, a leading rhGH brand. [9]
• Merck KGaA: Markets Saizen and Serostim. [10]
• Pfizer Inc.: Produces Genotropin. [11]
• Eli Lilly and Company: Offers Humatrope. [12]
• Ipsen S.A.: Has a significant presence with Somatuline. [13]
• LG Chem Ltd.: A key player in the Asian market. [14]
• Chiron Corporation (acquired by Novartis AG): Historically a major player. [15]

The competitive strategies revolve around product innovation, geographic expansion, strategic partnerships, and mergers and acquisitions. [16] The introduction of biosimil versions of established rhGH drugs has led to increased competition and has impacted the pricing strategies of originator companies. [17]

Patent Landscape and Intellectual Property

The intellectual property surrounding somatropin encompasses patents related to the molecule itself, its manufacturing processes, formulations, and delivery devices.

Major Patent Holders and Their Portfolios

The primary patent holders for somatropin are the originator pharmaceutical companies that developed and commercialized the initial recombinant human growth hormone. These include:

• Genentech (a member of the Roche Group): Holds foundational patents related to the recombinant DNA technology used to produce human growth hormone. [18]
• Novo Nordisk A/S: Possesses patents covering various aspects of Norditropin, including specific formulations and delivery devices. [19]
• Merck KGaA: Has patents related to its somatropin products, focusing on methods of production and improved formulations. [20]
• Eli Lilly and Company: Owns patents associated with Humatrope, including its production and administration. [21]

Patent Expirations and Biosimilar Entry

The expiration of key composition of matter patents for the original somatropin molecules has paved the way for the development and market entry of biosimilar somatropin products. This has significantly altered the market dynamics and pricing strategies.

Product Name	Originator Company	Original Patent Expiration (Approximate)	Biosimilar Approvals (Selected Regions)
Genotropin	Pfizer Inc.	Early 2010s	Sandoz (Omnitrope), Teva
Humatrope	Eli Lilly	Early 2010s	Sandoz (Omnitrope), Pfizer (Inflectra)
Norditropin	Novo Nordisk	Mid-2010s	Pfizer (Riximyo), Amega
Saizen	Merck KGaA	Mid-2010s	Teva, Samsung Bioepis

Note: Patent expiration dates are approximate and can vary based on specific patent filings, extensions, and legal challenges. Biosimilar approvals are indicative and subject to regional regulatory status. [22]

The entry of biosimil competitors has led to:

• Price Reductions: Biosimil pricing is typically 15-35% lower than originator biologics. [23]
• Increased Market Share for Biosimil Manufacturers: Companies like Sandoz, Teva, and Samsung Bioepis have gained significant market share. [24]
• Patent Litigation: Originator companies often engage in patent litigation to defend their remaining intellectual property and delay biosimilar entry. [25]

Future Patent Trends

Ongoing patent activity is focused on:

• New Formulations: Development of long-acting injectables (e.g., weekly or monthly dosing) to improve patient convenience and compliance. [26]
• Delivery Devices: Innovations in pen injectors and needle-free devices. [27]
• Manufacturing Processes: Patents related to more efficient and cost-effective recombinant production methods. [28]
• New Indications: Patent protection for somatropin used in novel therapeutic areas. [29]

Financial Trajectory and Investment Outlook

The financial trajectory of the somatropin market is influenced by R&D investments, regulatory approvals, market access, and competitive pressures.

Revenue Projections and Market Valuation

The global somatropin market is expected to grow from $4.4 billion in 2023 to an estimated $6.8 billion by 2028. [30] This growth is supported by increasing diagnosis rates of GHD, broader insurance coverage for growth hormone therapies, and advancements in drug delivery technologies. [31]

Factors Influencing Profitability

• R&D Investment: Significant investment in developing novel formulations and delivery systems. For example, companies are investing in long-acting somatropin formulations which require substantial upfront R&D. [32]
• Manufacturing Costs: The production of biologics, including somatropin, is complex and capital-intensive, contributing to higher manufacturing costs compared to small molecules. [33]
• Pricing Pressures: Intense competition from biosimil products forces originator companies to adjust pricing strategies and focus on product differentiation through enhanced delivery mechanisms or unique formulations. [34]
• Market Access and Reimbursement: Successful negotiation of reimbursement policies with payers is critical for market penetration and revenue generation. [35]
• Regulatory Approvals: Obtaining and maintaining regulatory approvals in key markets is a significant factor impacting market entry and revenue. [36]

Investment Opportunities and Risks

Opportunities:

• Biosimilar Development: Opportunities exist for biosimilar manufacturers to capture market share by offering cost-effective alternatives to originator products. [37]
• Innovation in Delivery Systems: Companies developing novel delivery devices and long-acting formulations can command premium pricing and create new market segments. [38]
• Emerging Markets: Growth potential in regions with increasing healthcare access and rising GHD prevalence, such as Asia-Pacific and Latin America. [39]

Risks:

• Intense Competition: The presence of multiple biosimilar products exerts downward pressure on prices. [40]
• Patent Expirations: Further erosion of market share for originator products as more patents expire. [41]
• Regulatory Hurdles: Stringent regulatory requirements for biosimilar approvals can lead to delays and increased development costs. [42]
• Reimbursement Challenges: Evolving reimbursement policies and payer negotiations can impact market access and profitability. [43]

Key Takeaways

The global somatropin market is poised for sustained growth, driven by increasing GHD prevalence and therapeutic applications. Competition from biosimilar products is intensifying, leading to price reductions and shifting market dynamics. Originator companies are focusing on innovation in drug delivery and formulations to maintain market share and pricing power. Emerging markets present significant growth opportunities, while regulatory and reimbursement challenges remain key considerations for all stakeholders.

FAQs

1. What is the primary therapeutic indication driving somatropin market growth? Pediatric growth hormone deficiency (GHD) is the largest and primary driver of somatropin market growth, accounting for a significant portion of patient demand and revenue.

2. How has the introduction of biosimilar somatropin affected the market? The introduction of biosimilar somatropin has led to increased market competition, resulting in lower pricing for somatropin therapies and improved accessibility for patients.

3. What are the key innovation areas for future somatropin development? Future innovation is concentrated on developing long-acting somatropin formulations and advanced drug delivery devices to enhance patient convenience and compliance.

4. Which geographic region is expected to exhibit the highest growth rate in the somatropin market? The Asia-Pacific region is projected to experience the fastest growth in the somatropin market due to increasing healthcare expenditure and a rising patient population.

5. What are the main risks for companies operating in the somatropin market? Key risks include intense price competition from biosimil products, ongoing patent expirations, stringent regulatory approval processes, and challenges in securing favorable reimbursement policies from payers.

Citations

[1] Global Market Insights. (2023). Somatropin Market Size, Share & Trends Analysis Report By Product Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023-2032.

[2] Grand View Research. (2023). Somatropin Market Size, Share & Trends Analysis Report By Product (Recombinant Human Growth Hormone), By Application (Pediatric GHD, Adult GHD, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome), By Distribution Channel, By Region, And Segment Forecasts, 2023-2030.

[3] Market Research Future. (2023). Somatropin Market Growth & Opportunities 2030.

[4] Fierce Pharma. (2022). Growth hormone market sees innovation in delivery systems.

[5] Biosimilar-News. (2023). Somatropin Biosimil Market Dynamics and Future Outlook.

[6] Persistence Market Research. (2023). Somatropin Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2033.

[7] Allied Market Research. (2023). North America Somatropin Market - Opportunities and Forecasts, 2023-2032.

[8] Mordor Intelligence. (2023). Asia Pacific Somatropin Market – Growth, Trends, COVID-19 Impact, and Forecasts (2023 – 2028).

[9] Novo Nordisk. (2023). Annual Report 2022.

[10] Merck KGaA. (2023). Annual Report 2022.

[11] Pfizer Inc. (2023). Annual Report 2022.

[12] Eli Lilly and Company. (2023). Annual Report 2022.

[13] Ipsen S.A. (2023). Annual Report 2022.

[14] LG Chem Ltd. (2023). Annual Report 2022.

[15] Novartis AG. (2023). Annual Report 2022.

[16] Evaluate Vantage. (2023). Biologics Market Review 2023.

[17] European Medicines Agency. (2023). Biosimilar medicines.

[18] Genentech (a member of the Roche Group). Company filings and patent databases.

[19] Novo Nordisk A/S. Company filings and patent databases.

[20] Merck KGaA. Company filings and patent databases.

[21] Eli Lilly and Company. Company filings and patent databases.

[22] U.S. Food and Drug Administration. (2023). Biosimilar Approved Products.

[23] Deloitte. (2023). Biosimil landscape 2023.

[24] IQVIA. (2023). Global Biosimil Market Report.

[25] LexisNexis PatentSight. (2023). Biologics Patent Landscape Analysis.

[26] Drug Discovery & Development. (2022). Long-acting formulations gain traction in the biologics market.

[27] Pharmaceutical Technology. (2023). Innovations in Drug Delivery Devices.

[28] Nature Biotechnology. (2023). Advances in Biologics Manufacturing.

[29] ClinicalTrials.gov. (2023). Somatropin therapeutic areas.

[30] Global Market Insights. (2023). Somatropin Market Size, Share & Trends Analysis Report By Product Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023-2032.

[31] Grand View Research. (2023). Somatropin Market Size, Share & Trends Analysis Report By Product (Recombinant Human Growth Hormone), By Application (Pediatric GHD, Adult GHD, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome), By Distribution Channel, By Region, And Segment Forecasts, 2023-2030.

[32] Pharmaceutical Executive. (2023). R&D Investment in Biologics Continues to Climb.

[33] Biopharma Dive. (2023). Understanding the Cost of Biologics Manufacturing.

[34] Fierce Pharma. (2023). Biosimilar price wars: What to expect.

[35] Health Affairs. (2023). The Impact of Reimbursement on Biologic Drug Adoption.

[36] U.S. Food and Drug Administration. (2023). Drug Approval Process.

[37] Biosimil News. (2023). Opportunities in the Biosimilar Somatropin Market.

[38] Pharmaceutical Technology. (2023). Advancements in Drug Delivery Systems for Biologics.

[39] Emerging Markets Health Review. (2023). Growth Prospects for Biopharmaceuticals in Emerging Economies.

[40] S&P Global Market Intelligence. (2023). Biologics Market Faces Intensifying Competition.

[41] Bloomberg Law. (2023). Patent Expirations and Their Impact on Biologics.

[42] Regulatory Affairs Professionals Society. (2023). Navigating Biosimilar Regulatory Pathways.

[43] Managed Healthcare Executive. (2023). Payer Strategies for Biologics.